IP Library Granted Patent US 7,638,487
Granted Patent B2
US 7,638,487 · App. 11/947,345 · Granted Dec 29, 2009

Lactoferrin in the reduction of pain

Assignee: Agennix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,638,487
App. No.
11/947,345
Granted
Dec 29, 2009
Kind
B2
Abstract

The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.

Claims (12)

1. A method of treating a subject suffering from pain comprising the step of administering to the subject an effective amount of a lactoferrin composition to provide a temporary improvement in pain in the subject, wherein the pain is associated with cancer and wherein said lactoferrin composition comprises an N-terminal lactoferrin variant with a deletion, substitution, or combination thereof, of from 1 to 16 N-terminal amino acid residues and the N-terminal lactoferrin variant retains the same biological function as full length lactoferrin.

2. The method of claim 1 , wherein the pain associated with cancer is chronic pain.

3. The method of claim 1 , wherein the N-terminal lactoferrin variant lacks at least the N-terminal glycine residue.

4. The method of claim 3 , wherein said N-terminal lactoferrin variant comprises at least 1% to at least 50% w/w of the lactoferrin composition.

5. The method of claim 1 , further comprising administering an antacid in conjunction with said lactoferrin composition.

6. The method of claim 1 , wherein the lactoferrin composition is administered in a delayed release formulation.

7. The method of claim 6 , wherein the lactoferrin composition is formulated for release in the small intestine.

8. The method of claim 6 , wherein the lactoferrin composition is formulated for release in the large intestine.

9. The method of claim 1 , wherein the amount of the composition that is administered comprises about 1 ng to about 100 g of lactoferrin per day.

10. The method of claim 1 , wherein the amount of the composition that is administered comprises about 0.1 g to about 10 g of lactoferrin per day.

11. The method of claim 1 , wherein said lactoferrin composition reduces the production or activity of pro-inflammatory cytokines.

12. The method of claim 1 , wherein said lactoferrin composition enhances the production or activity of cytokines that enhance an immune response.

Assignments (1)
SECURITY AGREEMENT Recorded Mar 16, 2009
From: AGENNIX INCORPORATED
To: GPC BIOTECH AG
Reel/Frame 022399/0104 →
Continuity (4)
Continuation 1073362100 · Dec 11, 2003
Provisional Application 6043293700 · Dec 12, 2002
Provisional Application 6049824800 · Aug 27, 2003
Related Publication 20080070833A1 · Mar 20, 2008